Web-based dosing calculators
Live demoApixaban dose calculator — NVAF and VTE demo
A live product-style dosing demo: Cockcroft–Gault creatinine clearance with UK lab units (µmol/L), side-by-side NVAF (2-of-3 reduction criteria plus renal-band handling) and VTE (phase-only dosing). Built to show how Eye4Health ships governed, explainable decision support — calm enough for the boardroom, precise enough for medical review — not for prescribing.
Published: 27 April 2026
Updated: 27 April 2026
Interactive dosing demo
Governed dosing support
Logic is explicit and versionable — suitable material for governance, MLR-style review, and deployment discussions.
UK unit-safe inputs
Serum creatinine captured in µmol/L and CrCl reported in mL/min — how UK labs and formularies typically talk.
Explainable rule logic
NVAF shows criterion-level outputs; VTE stays on a phase schedule — no accidental mixing of pathways.
Responsive by design
Works cleanly from desktop to phone so field, market access, and medical can share one link.
Layout preview
Optional tablet and phone widths for stakeholder reviews. Full width remains the default.
Shared inputs (both modes)
Whole years.
Use kilograms for this demo.
UK units: micromoles per litre (µmol/L).
Active mode — NVAF
Dose follows the 2-of-3 reduction grid and renal-band rules modelled here. This is not the VTE phase schedule.
Creatinine clearance — shared estimate
Shown in both NVAF and VTE so reviewers can compare CrCl with pathway-specific outputs.
68.7 mL/min
Cockcroft–Gault: ((140 − age) × weight × constant) ÷ serum creatinine, with constant 1.23 (male) or 1.04 (female); creatinine in µmol/L; result in mL/min.
NVAF dose output — criterion & renal logic
Below reflects NVAF showroom rules only.
NVAF: 5 mg twice daily
NVAF outcome type: Standard dose
NVAF only — 2-of-3 dose-reduction criteria
Criteria met (count): 0 of 3. Reduced dose if at least two are true (unless renal band below overrides — see methodology).
Age ≥ 80 years
Criterion met — no
Weight ≤ 60 kg
Criterion met — no
Serum creatinine ≥ 133 µmol/L
Criterion met — no
Demonstration only — not a prescribing tool
Use this page to judge how Eye4Health could deliver governed dosing support in your environment. Always follow current UK product information, the BNF, applicable NICE Technology Appraisals and guidance, MHRA communications, and local governance — clinical decisions stay with the prescriber.
How to read this interactive demo
What you are seeing: a working calculator surface with two distinct clinical models — NVAF (criterion and renal-band logic) and VTE (phase schedule only) — sharing the same UK-native CrCl estimate for transparency.
Capability on show: explainable rules, audit-friendly outputs, and production-minded engineering — the combination medical, market-access, and brand teams typically need before approving a vendor.
Why buyers care: dosing tools fail in procurement when logic is opaque. This demo makes the rule path and units visible so you can map it to your own governance and validation process.
Methodology, assumptions, and transparency
UK references (always verify). For real-world decisions, cross-check the current BNF, MHRA product information and safety updates, relevant NICE Technology Appraisals and other published guidance, and local formulary policy. This demo does not reproduce those sources in full.
Creatinine clearance. Estimated with the Cockcroft–Gault equation using total body weight (kg), age (years), serum creatinine in µmol/L, and sex-specific constants (male 1.23, female 1.04), per the showroom specification — alongside how CrCl is commonly discussed alongside BNF dosing tables in UK practice. Output is labelled in mL/min.
NVAF branch. Standard dose is 5 mg twice daily. Reduced dose is 2.5 mg twice daily if at least two of: age ≥ 80, weight ≤ 60 kg, serum creatinine ≥ 133 µmol/L. If CrCl is 15–29 mL/min, the demo applies 2.5 mg twice daily as a renal override. If CrCl is below 15 mL/min, the demo reports “avoid / not suitable” for routine use in this context — it does not output a maintenance dose.
VTE branch. Doses follow the selected phase only: initial treatment (days 1–7) 10 mg twice daily; ongoing (day 8 onwards) 5 mg twice daily; extended prevention (after 6 months) 2.5 mg twice daily. No additional renal adjustment is applied in this demo beyond displaying CrCl.
What is intentionally out of scope. Paediatric use, interactions, adherence, switching, peri-procedural management, body-composition adjustments beyond stated inputs, and any dosing rule not listed above.
The problem we are addressing
Commercial and medical stakeholders judge digital dosing tools on credibility: wrong units, opaque rules, or buried assumptions sink workshops. Buyers need to see methodology, governance, and UX discipline before they trust a vendor with production rollout.
What Eye4Health demonstrates here
- Shows creatinine clearance via Cockcroft–Gault with serum creatinine in µmol/L — the formula and sex-specific constants sit beside the number so reviewers can challenge it in real time.
- NVAF pathway surfaces standard versus reduced dosing using the showroom 2-of-3 criterion grid plus explicit renal-band handling — each outcome is labelled (standard, reduced by criteria, reduced by renal override, or avoid in this demo context).
- VTE pathway uses a separate phase schedule (initial, ongoing, extended prevention) only; CrCl stays visible for transparency but NVAF reduction rules are never mixed in.
Governance, inputs, and related work
Inputs, governance framing, and related Eye4Health capabilities — summarised below so the dosing surface above stays the focus.
Inputs
- Age (years), total body weight (kg), biological sex (male / female), serum creatinine (µmol/L).
- VTE mode additionally uses a fixed phase selector (initial treatment, ongoing treatment, extended prevention).
Governance and appropriate use
- Demonstration only — not for prescribing decisions. Always cross-check current BNF and SmPC, relevant NICE guidance, MHRA advice, and local formulary policy.
- This build encodes a fixed showroom rule set for buyer review; production deployments require your governance, validation, and evidence sign-off.
Related Eye4Health capabilities
- AATD prevalence — population planning demo
Related showroom: transparent methodology in another therapeutic context.
- Healthcare data visualisation